Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 10/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL904481 | 1.00 | SLC7A5 (0.42) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL900060 | 0.83 | SLC7A5 (0.43) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL900062 | 0.83 | SLC7A5 (0.43) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL2639452 | 0.81 | TAAR1 (0.46) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL2639451 | 0.81 | TAAR1 (0.46) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL9539354 | 0.81 | SLC7A5 (0.46) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL9539351 | 0.81 | SLC7A5 (0.46) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL7517353 | 0.81 | TAAR1 (0.46) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL8776731 | 0.81 | CTSC (0.42) | SLC7A5TAAR1SLC6A2MEN1CYP1A2 | |
| SCHEMBL8776735 | 0.81 | CTSC (0.42) | SLC7A5TAAR1SLC6A2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1642588-A2 | Mimetics of interleukin-8 and methods of using them in the prevention, treatment, diagnosis, and ameliorization of symptoms of a disease | Chemokine Therapeutics Corporation (CA) | 2006-04-05 | — | — | EP | claimed |
| CN-118202041-A | Background specific adenine base editor and application thereof | 布罗德研究所股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-116685682-A | Guided editing guide RNAs, compositions thereof, and methods of using the same | 布罗德研究所股份有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116490610-A | Methods and compositions for modulating genome | 旗舰先锋创新VI有限责任公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116209770-A | Methods and compositions for modulating genomic improvement | 旗舰先锋创新VI有限责任公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-116209756-A | Methods and compositions for modulating genome | 旗舰先锋创新VI有限责任公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-116096873-A | Methods and compositions for editing two strands of a target double-stranded nucleotide sequence simultaneously | 布罗德研究所股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2023280331-A1 | INSULIN DERIVATIVES WITH ENHANCED THERMAL STABILITY | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V. V. I. (CZ) | 2023-01-12 | — | — | WO | disclosed |
| CN-108303546-B | Method for identifying thyroid disease risk | 基酶有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-114127285-A | Methods and compositions for editing nucleotide sequences | 布罗德研究所股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-1996028471-A1 | MODULATORS OF AMYLOID AGGREGATION | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 1996-09-19 | — | — | WO | disclosed |
| WO-1995020317-A1 | METHOD FOR MAKING UNIVERSAL DONOR CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-08-03 | — | — | WO | disclosed |
| EP-0452040-B1 | Polysaccharide compounds produced by fermentation | KYOWA HAKKO KOGYO KK (JP) | 1995-07-12 | — | — | EP | disclosed |
| US-5252342-A | Administering prior to or concurrrently | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0460100-A1 | LIPOSOME GEL COMPOSITION AND METHOD | LIPOSOME TECHNOLOGY, INC. (US) | 1991-12-11 | — | — | EP | disclosed |
| EP-0452040-A2 | Polysaccharide compounds produced by fermentation | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1991-10-16 | — | — | EP | disclosed |
| EP-0405763-A1 | GRF peptides | MALLINCKRODT VETERINARY LIMITED (GB) | 1991-01-02 | — | — | EP | disclosed |
| WO-1990015073-A1 | GRF PEPTIDES | COOPERS ANIMAL HEALTH LIMITED (GB) | 1990-12-13 | — | — | WO | disclosed |
| WO-1990009782-A1 | LIPOSOME GEL COMPOSITION AND METHOD | LIPOSOME TECHNOLOGY, INC. (US) | 1990-09-07 | — | — | WO | disclosed |
| US-4944948-A | EPIDERMAL GROWTH FACTOR AS A WOUND HEALING AGENT; SUSTAINED RELEASE | LIPOSOME TECHNOLOGY, INC. (US) | 1990-07-31 | — | — | US | disclosed |